PFE · 8-K · 20260804PR000094
Specialty Care Growth
PFIZER INC · 2026-08-04 · Importance 64 · Surprise 56 · No source text
Specialty Care revenue rose 9% worldwide to $3.353 billion in the second quarter and 10% to $6.292 billion for the first six months. Vyndaqel family revenue increased 9% worldwide and 12% internationally in the quarter, reaching $1.762 billion. Octagam revenue grew 43% to $138 million, while Cibinqo increased 38% to $94 million, with U.S. and international growth of 39% and 37%, respectively. Xeljanz declined 22% worldwide and 32% in the U.S., reflecting weakness in an established specialty product.
Key facts
- Vyndaqel family revenues for Six Months 2026: $3,364 million, up 8% (or 6% operational) versus 2025; U.S. $1,975 million flat; International $1,389 million up 23% source
- Vyndaqel family global operational growth: up 8% in Q2 2026 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +1.7% | Vyndaqel family revenues for Six Months 2026: $3,364 million, up 8% (or 6% operational) versus 2025; U.S. $1,975 million flat;… |